scPharmaceuticals, Inc. (NASDAQ:SCPH) Stake Lowered by AIGH Capital Management LLC

AIGH Capital Management LLC cut its holdings in scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 1.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,096,367 shares of the company's stock after selling 78,000 shares during the quarter. scPharmaceuticals comprises 4.5% of AIGH Capital Management LLC's holdings, making the stock its 5th largest position. AIGH Capital Management LLC owned 8.15% of scPharmaceuticals worth $10,773,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SCPH. Rice Hall James & Associates LLC raised its position in scPharmaceuticals by 41.3% during the first quarter. Rice Hall James & Associates LLC now owns 1,398,057 shares of the company's stock valued at $3,677,000 after acquiring an additional 408,422 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in scPharmaceuticals during the first quarter valued at approximately $33,000. Rhumbline Advisers raised its position in scPharmaceuticals by 21.0% during the first quarter. Rhumbline Advisers now owns 51,499 shares of the company's stock valued at $135,000 after acquiring an additional 8,945 shares in the last quarter. Wealthedge Investment Advisors LLC purchased a new position in scPharmaceuticals during the fourth quarter valued at approximately $69,000. Finally, ProShare Advisors LLC purchased a new position in scPharmaceuticals during the fourth quarter valued at approximately $48,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Price Performance

SCPH traded down $0.45 during trading on Friday, hitting $5.39. The company's stock had a trading volume of 224,428 shares, compared to its average volume of 384,884. The company has a current ratio of 5.48, a quick ratio of 4.61 and a debt-to-equity ratio of 3.86. scPharmaceuticals, Inc. has a twelve month low of $1.94 and a twelve month high of $6.28. The business's fifty day simple moving average is $4.06 and its 200 day simple moving average is $3.33. The firm has a market capitalization of $284.60 million, a price-to-earnings ratio of -2.84 and a beta of 0.38.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The business had revenue of $11.75 million during the quarter, compared to analyst estimates of $11.63 million. scPharmaceuticals had a negative net margin of 216.24% and a negative return on equity of 594.07%. On average, equities research analysts forecast that scPharmaceuticals, Inc. will post -1.53 EPS for the current fiscal year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.